CXCL1 Antibody (C-Term)
Peptide-affinity purified goat antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application ![]()
| E |
---|---|
Primary Accession | P09341 |
Other Accession | NP_001502.1, 2919 |
Predicted | Human |
Host | Goat |
Clonality | Polyclonal |
Concentration | 0.5 mg/ml |
Isotype | IgG |
Calculated MW | 11301 Da |
Gene ID | 2919 |
---|---|
Other Names | Growth-regulated alpha protein, C-X-C motif chemokine 1, GRO-alpha(1-73), Melanoma growth stimulatory activity, MGSA, Neutrophil-activating protein 3, NAP-3, GRO-alpha(4-73), GRO-alpha(5-73), GRO-alpha(6-73), CXCL1, GRO, GRO1, GROA, MGSA, SCYB1 |
Format | 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | CXCL1 Antibody (C-Term) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | CXCL1 |
---|---|
Synonyms | GRO, GRO1, GROA, MGSA, SCYB1 |
Function | Has chemotactic activity for neutrophils. May play a role in inflammation and exerts its effects on endothelial cells in an autocrine fashion. In vitro, the processed forms GRO-alpha(4-73), GRO- alpha(5-73) and GRO-alpha(6-73) show a 30-fold higher chemotactic activity. |
Cellular Location | Secreted. |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
References
Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder cancer Kawanishi H, Matsui Y, Ito M, Watanabe J, Takahashi T, Nishizawa K, Nishiyama H, Kamoto T, Mikami Y, Tanaka Y, Jung G, Akiyama H, Nobumasa H, Guilford P, Reeve A, Okuno Y, Tsujimoto G, Nakamura E, Ogawa O Clin. Cancer Res. 2008 May 14 (9): 2579-87 PMID: 18451219

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.